Banque Cantonale Vaudoise Has $8.71 Million Stock Position in Gilead Sciences, Inc. $GILD

Banque Cantonale Vaudoise reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,964 shares of the biopharmaceutical company’s stock after selling 9,314 shares during the period. Banque Cantonale Vaudoise’s holdings in Gilead Sciences were worth $8,710,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $28,000. Financial Consulate Inc. grew its position in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares in the last quarter. North Star Investment Management Corp. increased its stake in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 86 shares during the period. MTM Investment Management LLC lifted its position in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares in the last quarter. Finally, BOCHK Asset Management Ltd purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $31,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Royal Bank Of Canada lowered their price target on shares of Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a report on Friday, May 8th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. BMO Capital Markets upped their target price on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Wells Fargo & Company raised their price target on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Finally, Daiwa Securities Group reduced their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $156.62.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares in the company, valued at $22,907,973.57. This trade represents a 1.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 63,000 shares of company stock worth $8,523,570. 0.30% of the stock is owned by insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead was highlighted in a hedge-fund screen as one of the “best long-term low-risk stocks,” which may reinforce the view that institutional investors see it as a relatively defensive large-cap healthcare name. 5 Best Long Term Low Risk Stocks to Buy According to Hedge Funds
• Positive Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference, keeping investor focus on Gilead’s HIV, oncology, and pipeline outlook following its recent earnings beat. Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
• Positive Sentiment: Daiwa Securities lowered its price target to $150 from $161 but kept an Outperform rating, suggesting the firm still sees upside from current levels despite the cut.
• Positive Sentiment: Recent commentary around Gilead’s Q1 results pointed to solid execution, including strong HIV franchise performance and momentum in oncology, which supports the stock’s valuation. Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
• Neutral Sentiment: Gilead’s CFO and another senior insider disclosed stock sales, but both were made under pre-arranged 10b5-1 plans, which limits the bearish signal. Gilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in Stock
• Negative Sentiment: Despite the constructive backdrop, analyst target cuts and insider selling may be creating some caution and helping cap gains in the near term.

Gilead Sciences Trading Up 0.6%

Gilead Sciences stock opened at $130.50 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The company has a market capitalization of $162.02 billion, a price-to-earnings ratio of 17.78 and a beta of 0.31. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29. The company’s fifty day moving average price is $137.18 and its two-hundred day moving average price is $133.48.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.